Navigation Links
HRT Update: Therapy May Reduce Fractures, Boost Some Risks
Date:5/29/2012

By Kathleen Doheny
HealthDay Reporter

MONDAY, May 28 (HealthDay News) -- Updated evidence on hormone replacement therapy for menopausal women presents good news for those at risk of osteoporosis, but a mixed bag of results regarding breast cancer and other chronic diseases.

While estrogen-only and estrogen-plus-progestin formulations reduce the risk of fractures, both increase the odds for stroke and other conditions including gallbladder disease, according to a new update of available evidence compiled for the U.S. Preventive Services Task Force, an independent expert panel that is revising its guidelines.

Estrogen-plus-progestin therapy raises the risk of breast cancer and probable dementia, while estrogen alone reduces the risk of breast cancer, the researchers found.

"We looked at all the published studies on hormone therapy for the prevention of chronic disease," said Dr. Heidi Nelson, who led the update. "What is new here is, we've taken all the results from the last 10 years and tried to distill them into the latest, most current results and how they might apply to individuals."

Some protective effects found in earlier research now appear weaker, added Nelson, a professor of medical informatics, clinical epidemiology and medicine at the Oregon Health & Science University, in Portland. Similarly, some risks look even stronger.

The findings are published online May 29 in the Annals of Internal Medicine.

Years ago, hormone therapy was often prescribed to prevent chronic conditions such as osteoporosis and cardiovascular disease. But initial results of the Women's Health Initiative study, published in 2002, found harmful effects for estrogen-plus-progestin regimens. Two years later, serious alarms were raised about estrogen-only therapy.

As a result, the task force recommended against both types of treatment for prevention of chronic disease.

Now, with about 11 years of follow-up to the Women's Health Initiative, researchers have a fuller picture, which the task force will use to update its existing guidelines.

The recommendations concern only chronic disease, not the use of hormone therapy for reducing symptoms of menopause, such as hot flashes.

For the update, Nelson and her team looked at 51 published articles, involving nine research trials, that met their criteria.

They confirmed that both estrogen alone and combination therapy reduce the risk of fractures, as found before. But they concluded that both types of treatment increase the risk of stroke, blood clots, gallbladder disease and urinary incontinence.

While estrogen alone seems to reduces the risk of breast cancer, they found stronger evidence than before that combination therapy increases the risk for breast cancer. For every 10,000 women, eight more cases of breast cancer per year are expected in those on combination therapy, Nelson said.

Women who smoke, used birth control pills or took combination therapy for symptoms of menopause have higher risks of breast cancer, they found.

Estrogen-only therapy appears to reduce invasive breast cancer by about the same amount, she said, but cautioned that it's not a reason for taking it. This effect is stronger than before, Nelson said.

Other changes: Initial results indicated that those on combination therapy had a significant increased risk for heart disease. Now, that association appears weaker, she said.

Previously, the estrogen-progestin combination was thought to protect against colon cancer. That link also looks weaker, she said.

Nelson said the differences in risks and benefits are probably explained more by the risk profiles of the women who take each therapy rather than the progestin or its lack in the therapy itself. The women have different risk factors to begin with, she said. For instance, many taking only estrogen have had a hysterectomy, with their uterus and ovaries removed, she said.

Bottom line? It does not appear wise to take hormone therapy long-term to prevent chronic conditions, she said. The best strategy remains to take the therapy, if needed for symptoms, at the lowest dose for the shortest time possible.

Given the different risks associated with estrogen-only and combination therapy, it's important to discuss your individual health history with your doctor, experts said.

Dr. Jill Rabin, chief of ambulatory care, obstetrics and gynecology at Long Island Jewish Medical Center, in New Hyde Park, N.Y., agreed that short-term, low-dose therapy for relief of symptoms is the best strategy.

Another option, she tells her patients, is to "think local." Some women are helped by estrogen cream or estrogen vaginal rings, she said.

More information

To learn more about hormone therapy, visit the U.S. National Institutes of Health.

SOURCES: Heidi D. Nelson, M.D., M.P.H., professor of medical informatics, clinical epidemiology and medicine, Oregon Health & Science University, Portland; Jill Rabin, M.D., chief of ambulatory care, obstetrics and gynecology, head of urogynecology, Long Island Jewish Medical Center, New Hyde Park, N.Y.; May 29, 2012, Annals of Internal Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Update: MedQuist Wins Contract with Detroit Medical Center for Emergency Medicine Transcription at Six Healthcare Organizations
2. Study update: Cancer information on Wikipedia is accurate, but not very readable
3. Nicotine replacement therapy is over-promoted since most ex-smokers quit unassisted
4. Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy
5. Longview Therapy Center, PLLC, Unveils Its Definition Of Hope
6. Short-term radiation therapy successful on breast cancer
7. ASCROs Response to NY Times Articles on Radiation Therapy Incidents
8. Children With Cerebral Palsy Benefitting From New Physical Therapy Regimen
9. DavisPTnetwork Partners with the New York Physical Therapy Association to Provide Online Continuing Education
10. Behavioral therapy improves sleep and lives of patients with pain
11. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HRT Update: Therapy May Reduce Fractures, Boost Some Risks
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: